DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

12 май 2022 16:00:00 Источник Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

11 май 2022 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

09 май 2022 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

28 апр 2022 16:30:00 Источник Nasdaq GlobeNewswire

Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

13 апр 2022 08:52:30 Источник Nasdaq GlobeNewswire

Dyadic International to Present at Upcoming Scientific Medical Meetings

04 апр 2022 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic Reports 2021 Year End Results and Recent Company Progress

29 мар 2022 16:00:00 Источник Nasdaq GlobeNewswire

Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

15 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

10 фев 2022 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

07 фев 2022 08:30:01 Источник Nasdaq GlobeNewswire

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

20 янв 2022 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

22 дек 2021 09:12:47 Источник Nasdaq GlobeNewswire

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

17 дек 2021 07:00:00 Источник Nasdaq GlobeNewswire

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

10 ноя 2021 16:00:00 Источник Nasdaq GlobeNewswire

Dyadic Appoints Chief Business Officer to Executive Leadership Team

09 ноя 2021 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

27 окт 2021 16:30:00 Источник Nasdaq GlobeNewswire

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

10 сен 2021 08:30:00 Источник Nasdaq GlobeNewswire

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

11 авг 2021 08:35:40 Источник Nasdaq GlobeNewswire

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

27 июл 2021 08:20:00 Источник Nasdaq GlobeNewswire

Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

28 июн 2021 08:30:00 Источник Nasdaq GlobeNewswire